HeartSciences (HSCS) Expected to Post Earnings on Thursday

HeartSciences (NASDAQ:HSCS) is expected to be issuing its Q4 2026 results before the market opens on Thursday, July 23rd. Analysts expect HeartSciences to announce earnings of ($0.66) per share and revenue of $0.05 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Friday, July 31, 2026 at 4:00 PM ET.

HeartSciences Stock Performance

HeartSciences stock opened at $2.57 on Tuesday. The company has a current ratio of 1.19, a quick ratio of 1.04 and a debt-to-equity ratio of 0.16. The firm has a market cap of $8.17 million, a P/E ratio of -0.52 and a beta of 1.78. HeartSciences has a 1-year low of $1.63 and a 1-year high of $4.30. The firm has a 50-day moving average of $2.23 and a 200-day moving average of $2.52.

Institutional Investors Weigh In On HeartSciences

A hedge fund recently raised its position in HeartSciences stock. DRW Securities LLC increased its stake in HeartSciences Inc. (NASDAQ:HSCS) by 13.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 95,065 shares of the company’s stock after buying an additional 11,455 shares during the period. DRW Securities LLC owned 2.99% of HeartSciences worth $294,000 at the end of the most recent reporting period. 17.24% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on HSCS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. Ascendiant Capital Markets reduced their target price on HeartSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.